Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7525 in Advanced Prostate Cancer
NCT07711184Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HRS-7525 in prostate cancer (PCa), sponsored by Hengrui. Primary endpoints: Dose Limiting Toxicity at 23 days, Maximum Tolerated Dose at 13 months and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
HRS-7525
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07711184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711184.